نتایج جستجو برای: abl positive

تعداد نتایج: 663991  

Journal: :Blood 1988
M S Lee K S Chang E J Freireich H M Kantarjian M Talpaz J M Trujillo S A Stass

The Philadelphia (Ph1) chromosome in chronic myelogenous leukemia (CML) involves reciprocal translocation of the bcr gene and the c-abl oncogene. The fused bcr/abl gene is transcribed into two types of chimeric mRNA. By means of a combined method of S1 nuclease protection and polymerase chain reaction, we amplified sequences representative of the chimeric bcr/abl transcripts. Only 5 micrograms ...

Journal: :Blood 2000
E Weisberg J D Griffin

The tyrosine kinase activity of the Bcr/Abl oncogene is required for transformation of hematopoietic cells. The tyrosine kinase inhibitor STI571 (formerly called CGP57148B, Novartis Pharmaceuticals) inhibits BCR/ABL, TEL/ABL, and v-ABL kinase activity and inhibits growth and viability of cells transformed by any of these ABL oncogenes. Here we report the generation of 2 BCR/ABL-positive cell li...

Journal: :Cancer research 1995
T Skorski M Nieborowska-Skorska C Szczylik P Kanakaraj D Perrotti G Zon A Gewirtz B Perussia B Calabretta

BCR/ABL oncogenic tyrosine kinase is responsible for initiating and maintaining the leukeic phenotype of Philadelphia chromosome-positive cells. c-RAF-1 serine/threonine kinase is known to be activated by receptor and nonreceptor tyrosine kinases. To determine whether c-RAF-1 plays a role in the growth of BCR/ABL-dependent cells, we examined whether c-RAF-1 associates with and/or is regulated b...

Journal: :Zeitschrift fur Naturforschung. C, Journal of biosciences 2006
Ireneusz Majsterek Michal Arabski Agnieszka Czechowska Dariusz Pytel Zbigniew Morawiec Alina Morawiec-Bajda Janusz Blasiak

BCR/ABL oncogene, as a result of chromosome aberration t(9;22), is the pathogenic principle of almost 95% of human chronic myeloid leukemia (CML). Imatinib (STI571) is a highly selective inhibitor of BCR/ABL oncogenic tyrosine kinase used in leukemia treatment. It has been suggested that BCR/ABL may contribute to the resistance of leukemic cells to drug and radiation through stimulation of DNA ...

Journal: :Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2012
José Erasmo Vázquez-Franco Elba Reyes-Maldonado Laura Arcelia Montiel-Cervantes Ruth Angélica Lezama

INTRODUCTION The BCR-ABL t(9;22)(q34;q11) translocation has been identified as a risk factor in de novo acute lymphoblastic leukemia (ALL), but there are other factors that may influence survival in patients not expressing this translocation. OBJECTIVE To associate expression and non-expression of BCR-ABL with immunophenotype and other clinical features in adult patients with ALL from a Mexic...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2013
Pankaj Baral Sanjiv Neupane Basudha Shrestha Kashi Ram Ghimire Bishnu Prasad Marasini Binod Lekhak

Limited information is available regarding AmpC β-lactamase (ABL)-producing Enterobacteriaceae compared to extended-spectrum β-lactamase-producing enterobacteria. Since ABL-producing organisms are often resistant to multiple antimicrobial agents, therapeutic options against these pathogens are limited. Among 230 clinical Enterobacteriaceae isolates, 64 (27.8%) were found to produce ABL in our s...

Journal: :Blood 1999
G J ten Bosch J H Kessler A M Joosten A A Bres-Vloemans A Geluk B C Godthelp J van Bergen C J Melief O C Leeksma

Peptides corresponding to the fusion site in 210 kD BCR-ABL protein b3a2 (p210b3a2) were previously shown to bind to several HLA class I and II alleles. We have found that b3a2 peptide-specific CD4-positive T-helper cells were able to recognize p210b3a2-positive chronic myelogenous leukemia (CML) blasts in a DR4 restricted manner. Until now, there were no reports of b2a2 breakpoint-specific hum...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1998
M Beran X Cao Z Estrov S Jeha G Jin S O'Brien M Talpaz R B Arlinghaus N B Lydon H Kantarjian

The excessive proliferation of the myeloid marrow compartment in Philadelphia chromosome (Ph)-positive acute and chronic leukemias has been largely attributed to a hyperactive and autonomously acting hybrid tyrosine kinase BCR-ABL, a product of the fusion between the second exon of the c-ABL proto-oncogene and 5' portions of the BCR gene on chromosome 22. This specific molecular event, amenable...

Journal: :Cancer research 2007
Gisella Volpe Alessandro Cignetti Cristina Panuzzo Mirela Kuka Katiuscia Vitaggio Mara Brancaccio Giuseppe Perrone Monica Rinaldi Giuseppina Prato Milena Fava Massimo Geuna Marisa Pautasso Claudia Casnici Emanuela Signori Giancarlo Tonon Guido Tarone Ornella Marelli Vito M Fazio Giuseppe Saglio

Imatinib currently represents the standard treatment in the early chronic phase of chronic myelogenous leukemia (CML), thanks to the high percentage of cytogenetic complete remission achieved, but it is yet unclear to what extent it can eradicate leukemia. Therefore, different vaccination strategies have been suggested, mainly based on the exploitment of the junctional peptides spanning the fus...

Journal: :Cancer research 2003
Xiaoyang Ling Guozhen Ma Tong Sun Jiaxin Liu Ralph B Arlinghaus

c-Abl tyrosine kinase is under rigorous control because of an unknown cellular inhibitor that maintains c-Abl in a relatively inactive state. Because SH2 domains are positive regulators of the nonreceptor tyrosine kinases, we tested whether this putative inhibitor would bind to an Abl SH2 protein construct and thus activate the c-Abl tyrosine kinase. Expression of a Mr 10,000 Abl SH2 protein in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید